Compare WCC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WCC | GH |
|---|---|---|
| Founded | 1922 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 14.1B |
| IPO Year | 1999 | 2018 |
| Metric | WCC | GH |
|---|---|---|
| Price | $259.16 | $101.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | ★ $255.11 | $82.76 |
| AVG Volume (30 Days) | 514.3K | ★ 2.2M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 2.23 | N/A |
| EPS | ★ 12.73 | N/A |
| Revenue | ★ $22,942,100,000.00 | $902,569,000.00 |
| Revenue This Year | $8.59 | $34.72 |
| Revenue Next Year | $6.01 | $26.46 |
| P/E Ratio | $20.45 | ★ N/A |
| Revenue Growth | 5.28 | ★ 30.38 |
| 52 Week Low | $125.21 | $29.91 |
| 52 Week High | $279.04 | $112.43 |
| Indicator | WCC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 55.40 |
| Support Level | $263.83 | $100.21 |
| Resistance Level | $279.04 | $109.59 |
| Average True Range (ATR) | 8.46 | 4.22 |
| MACD | -0.91 | -1.65 |
| Stochastic Oscillator | 44.84 | 13.51 |
Wesco can be traced back to the late 1800s but was officially founded in 1922, acting as the distribution arm of Westinghouse Electric. Throughout the 1900s, Wesco entered and subsequently exited the consumer electronics, transit, bottling, and nuclear plant distribution markets. It was sold to a private equity firm in 1994 and then went public in 1999, and numerous acquisitions have since been made to fill the gaps in Wesco's geographical and product coverage. Today, the firm primarily distributes electrical, networking, security, and utility equipment used in the construction and repair of structures such as offices, data centers, power transmission lines, and manufacturing plants. Wesco has operations around the globe but generates the majority of its revenue in the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.